CochlearFRA:OC50 +0.58%73 EBITDA Margin % is 23.22% as of Dec. 2025, which is 14% below its 10-year median of 27.09. GuruFocus rates FRA:OC50 with a GF Score™ of 73/100 and a GF Value™ of €91.14 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Cochlear ranks better than 83.33% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cochlear's EBITDA for the
six
months ended in Dec. 2025 was €154 Mil. Cochlear's Revenue for the
six
months ended in Dec. 2025 was €662 Mil. Therefore, Cochlear's EBITDA margin for the quarter that ended in Dec. 2025 was 23.22%.
Cochlear (FRA:OC50) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cochlear EBITDA Margin % Related Terms
Cochlear EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cochlear's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OC50 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Cochlear's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cochlear EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cochlear's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cochlear (FRA:OC50) has a EBITDA Margin % of 23.22% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cochlear and its competitors. This is 14% below median its historical median of 27.09. According to the industry distribution chart, Cochlear ranks #136 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Cochlear's EBITDA Margin % too high?
Cochlear's current EBITDA Margin % of 23.22% is 14% below median its 10-year median of 27.09. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Cochlear's value of 23.22% is 210.6% above this industry median. Based on the distribution chart, Cochlear ranks #136 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cochlear has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #136 out of 816 companies for EBITDA Margin %. This places Cochlear in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Cochlear's value of 23.22% is 210.6% above this benchmark. While the company's 10-year median is 27.09 vs. the industry median of 7.48, Cochlear has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current EBITDA Margin % of 23.22% is 210.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current EBITDA Margin % is 23.22%, which is 14% below median its own 10-year median of 27.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (FRA:OC50) is currently considered Significantly Undervalued. The stock's GF Value™ is €91.14, compared to a current price of €34.40 — trading 62.3% below its estimated fair value. The current EBITDA Margin % is 23.22%, which is 14% below median its 10-year median of 27.09 and 210.6% above the Medical Devices & Instruments industry median of 7.48. Cochlear's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cochlear (FRA:OC50), the current EBITDA Margin % is 23.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cochlear (FRA:OC50) Overvalued in 2026?
Based on GuruFocus' analysis, Cochlear stock appears to be undervalued.
The current stock price of €34.40 is trading 62.3% below its estimated GF Value™ of €91.14.
GuruFocus considers Cochlear to be Significantly Undervalued.
Key valuation signals for FRA:OC50:
EBITDA Margin %: 23.22% (14% below median its 10-year median of 27.09)
GF Value™: €91.14 vs. price of €34.40 (62.3% below fair value)
Industry Position: 210.6% above the Medical Devices & Instruments median (#136 of 816)
No single metric tells the full story. See the FRA:OC50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
73GF Score
Get the complete analysis for FRA:OC50
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OC50 has been successfully added to your 
